What is Pacific Biosciences of California Current Ratio?
Pacific Biosciences of CaliforniaPACB +11.11%53 Current Ratio is 5.65 as of Mar. 2026, which is 16% above its 10-year median of 4.85. GuruFocus rates PACB with a GF Score™ of 53/100 and a GF Value™ of $1.62 (Fairly Valued). The stock has 8 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Pacific Biosciences of California ranks better than 81.15% on this metric.
Pacific Biosciences of California has a current ratio of 5.65. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Pacific Biosciences of California's Current Ratio or its related term are showing as below:
PACB'
s Current Ratio Range Over the Past 10 Years
Min: 1.15 Med: 4.85 Max: 35.45
Current: 5.65
During the past 13 years, Pacific Biosciences of California's highest Current Ratio was 35.45. The lowest was 1.15. And the median was 4.85.
PACB's Current Ratio is ranked better than 81.15% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.485
vs PACB: 5.65
Pacific Biosciences of California (NAS:PACB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Pacific Biosciences of California Current Ratio Related Terms
Pacific Biosciences of California Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California Current Ratio Chart
For the Medical Devices subindustry, Pacific Biosciences of California's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Biosciences of California Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Current Ratio distribution charts can be found below:
* The bar in red indicates where Pacific Biosciences of California's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California (PACB) has a Current Ratio of 5.65 as of Mar. 2026. This is 16% above median its historical median of 4.85. Over the past decade, Pacific Biosciences of California's Current Ratio has ranged from 1.15 to 35.45. According to the industry distribution chart, Pacific Biosciences of California ranks #161 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 18.9%.
Is Pacific Biosciences of California's Current Ratio too high?
Pacific Biosciences of California's current Current Ratio of 5.65 is 16% above median its 10-year median of 4.85. Over the past 10 years, this metric has ranged from a low of 1.15 to a high of 35.45. The Medical Devices & Instruments industry median Current Ratio is 2.49. Pacific Biosciences of California's value of 5.65 is 127.4% above this industry median. Based on the distribution chart, Pacific Biosciences of California ranks #161 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Pacific Biosciences of California has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Current Ratio compare to CATX and LAB?
According to the Medical Devices & Instruments industry distribution chart, Pacific Biosciences of California ranks #161 out of 854 companies for Current Ratio. This places Pacific Biosciences of California in the top 19% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.49. Pacific Biosciences of California's value of 5.65 is 127.4% above this benchmark. Historically, Pacific Biosciences of California's own Current Ratio has ranged from 1.15 to 35.45 over the past decade. While the company's 10-year median is 4.85 vs. the industry median of 2.49, Pacific Biosciences of California has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Biosciences of California's current Current Ratio of 5.65 is 127.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Biosciences of California's current Current Ratio is 5.65, which is 16% above median its own 10-year median of 4.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Fairly Valued. The stock's GF Value™ is $1.62, compared to a current price of $1.60 — trading 1.2% below its estimated fair value. The current Current Ratio is 5.65, which is 16% above median its 10-year median of 4.85 and 127.4% above the Medical Devices & Instruments industry median of 2.49. Pacific Biosciences of California's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Current Ratio is 5.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued.
The current stock price of $1.60 is trading 1.2% below its estimated GF Value™ of $1.62.
GuruFocus considers Pacific Biosciences of California to be Fairly Valued.
Key valuation signals for PACB:
Current Ratio: 5.65 (16% above median its 10-year median of 4.85)
GF Value™: $1.62 vs. price of $1.60 (1.2% below fair value)
Industry Position: 127.4% above the Medical Devices & Instruments median (#161 of 854)
No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Business Description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
53GF Score
Get the complete analysis for PACB
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PACB has been successfully added to your 
